Coherus BioSciences (CHRS) Tops Q3 EPS by 11c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.15 -4.17%
Financial Fact:
Income/(loss) from operations: 27.38M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Income/(loss) from operations: 27.38M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($0.27), $0.11 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $74.6 million versus the consensus estimate of $81.78 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla to launch Cybercab in Austin this month - report
- Is Treasury selloff a major issue for stock market bulls?
- Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
